Director Eric Dobmeier to not stand for re-election at Atara's 2024 annual meeting

Atara Biotherapeutics, Inc.

Eric Dobmeier notified Atara on March 26, 2024, he will not stand for re-election at the 2024 annual meeting.
He will continue as director until his term expires at the 2024 Annual Meeting.
No disagreement with Board or management; decision not related to operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Dobmeier

Director

ATRA · Atara Biotherapeutics, Inc.

Filed: March 29, 2024, 7:59 PM ET

On March 26, 2024, Eric Dobmeier, a member of the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to not stand for re-election to the Board at the Company’s 2024 annual meeting of stockholders (“2024 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Dobmeier departed as Director at Atara Biotherapeutics, Inc..

Action: not stand for re-election
Role: Director

Exact text from the filing

On March 26, 2024, Eric Dobmeier, a member of the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to not stand for re-election to the Board at the Company’s 2024 annual meeting of stockholders (“2024 Annual Meeting”).

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-038690

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.